5/5/2023 0 Comments Deep therapy cream ecMulti-Country Study to Evaluate Patient Satisfaction with a Dual Applicator Cryolipolysis System for Non-Invasive Fat Reduction in Abdomen, Flanks, Upper Arms, Inner Thighs, Outer Thighs, and Submental Area (Study Design) Hyaluronic Acid Filler VYC-25L for Jawline Restoration Yields High Satisfaction, Improved Jawline Measurements, and Sustained Effect Across Age, Gender, and Skin Types for up to 12 Monthsĭelayed-onset Nodules Following Vycross Hyaluronic Acid Filler Injections: Reported Rates From Global Post-marketing SurveillanceĪ Prospective, Open-Label Study to Evaluate Functional Changes Following Electromagnetic Muscle Stimulation of Abdominal Muscle Complete abstracts and details on presentation dates and times can be found on the ASDS website. By surveying over 4,000 women aged 21-65, from multiple geographic locations and backgrounds, the report explores what defines beauty, how beauty impacts women's lives, and the interplay between beauty and race. The report provides a new understanding of what inclusive and representative beauty looks like today by shedding light on how narrowly defined Eurocentric ideals continue to impact women of color. DiAnne Davis, a board-certified cosmetic dermatologist out of Dallas, Texas, will discuss the new Forces of Beauty ® Report from Allergan Aesthetics' DREAM (Driving Racial Equity in Aesthetic Medicine) Initiative ® at the Diversity, Equity and Inclusion (DEI) reception on Friday, October 7. ![]() The analyses of 15 years of data demonstrate the global reported rate of delayed-onset nodules associated with dermal fillers on the Vycross technology platform is low (Īdditionally, Dr. "The data presented at ASDS reinforces our leadership in aesthetics and also the commitment of our research and development team to drive innovation for the industry and share learnings with the broader medical community."Īt the meeting, researchers will spotlight global post-marketing surveillance data on the reported rates of delayed-onset nodules presenting four or more weeks after injection of hyaluronic acid fillers based on the Vycross technology platform. "Our scientific excellence continues to help drive advancements in aesthetic medicine, as well bring impactful treatments to our customers and patients globally," said Darin Messina, Senior Vice President, Allergan Aesthetics R&D. ![]() Data presented across a broad spectrum of aesthetic indications aims to further scientific research and improve patient outcomes. Īllergan Aesthetics has one of the largest, most-researched portfolio and pipeline in the medical aesthetics industry. 7, 2022 /PRNewswire/ - Allergan Aesthetics, an ABBVie company, (NYSE: ABBV) announced today that eight scientific abstracts from its leading portfolio of aesthetic products and treatments will be presented at the American Society for Dermatologic Surgery (ASDS) meeting taking place October 6-10 in Denver. ![]()
0 Comments
Leave a Reply. |